## This Page Is Inserted by IFW Operations and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

FIGURE

administration of metformin XT (2 x 850 mg q.d., lot No. P98237) or GLUCOPHAGE (850 mg b.i.d.) Mean plasma concentration-time profiles of metformin in eleven subjects after an oral





administration of metformin XT (4 x 500 mg q.d., lot No. P98231) or GLUCOPHAGE (2 x 500 mg b.i.c Mean plasma concentration-time profiles of metformin in twelve subjects after an oral




FIGURE 3

Mean plasma concentration-time profiles of metformin in eight healthy subjects after multiple oral doses of metformin XT (4 x 500 mg q.d.)






FIGURE 4

Mean steady-state plasma concentration-time profiles of metformin in NIDDM patients (n=23) — Metformin XT

— GLUCOPHAGE after multiple oral doses of metformin XT ( $2 \times 1000$  mg, q.d. with dinner) or 23 GLUCOPHAGE (1 x 1000 mg, b.l.d.) for 4 weeks 16 Time (hr) 2000 500 3000 2500 -1000 1500 Plasma conc. (ng/ml)

FIGURE 5








Fig 8

